|
1.
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
|
|
2.
|
Kudo M, Izumi N, Kokudo N, Matsui O,
Sakamoto M, Nakashima O, Kojiro M and Makuuchi M: HCC Expert Panel
of Japan Society of Hepatology. Management of hepatocellular
carcinoma in Japan: Consensus-Based Clinical Practice Guidelines
proposed by the Japan Society of Hepatology (JSH) 2010 updated
version. Dig Dis. 29:339–364. 2011. View Article : Google Scholar
|
|
3.
|
Lencioni R: Loco-regional treatment of
hepatocellular carcinoma. Hepatology. 52:762–773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. New Eng J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Guy J, Kelley RK, Roberts J, Kerlan R, Yao
F and Terrault N: Multidisciplinary management of hepatocellular
carcinoma. Clin Gastroenterol Hepatol. 10:354–362. 2012. View Article : Google Scholar
|
|
6.
|
Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP,
Pan ZY, Lau WY and Wu MC: A prospective, randomized, controlled
trial of preoperative transarterial chemoembolization for
resectable large hepatocellular carcinoma. Ann Surg. 249:195–202.
2009. View Article : Google Scholar
|
|
7.
|
Izumi R, Shimizu K, Iyobe T, Ii T, Yagi M,
Matsui O, Nonomura A and Miyazaki I: Postoperative adjuvant hepatic
arterial infusion of lipiodol containing anticancer drugs in
patients with hepatocellular carcinoma. Hepatology. 20:295–301.
1994. View Article : Google Scholar
|
|
8.
|
Nishiguchi S, Shiomi S, Nakatani S, Takeda
T, Fukuda K, Tamori A, Habu D and Tanaka T: Prevention of
hepatocellular carcinoma in patients with chronic active hepatitis
C and cirrhosis. Lancet. 357:196–197. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Shiratori Y, Shiina S, Teratani T, Imamura
M, Obi S, Sato S, Koike Y, Yoshida H and Omata M: Interferon
therapy after tumor ablation improves prognosis in patients with
hepatocellular carcinoma associated with hepatitis C virus. Ann
Intern Med. 138:299–306. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Papatheodoridis GV, Lampertico P,
Manolakopoulos S and Lok A: Incidence of hepatocellular carcinoma
in chronic hepatitis B patients receiving nucleos(t)ide therapy: a
systematic review. J Hepatol. 53:348–356. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Schwartz JD, Schwartz M, Mandeli J and
Sung M: Neoadjuvant and adjuvant therapy for resectable
hepatocellular carcinoma: review of the randomized clinical trials.
Lancet Oncol. 3:593–603. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Ishikawa T, Higuchi K, Kubota T, Seki K,
Honma T, Yoshida T and Kamimura T: Prevention of intrahepatic
distant recurrence by transcatheter arterial infusion chemotherapy
with platinum agents for stage I/II hepatocelluar carcinoma.
Cancer. 117:4018–4025. 2011. View Article : Google Scholar
|
|
13.
|
Chua TC, Liauw W, Saxena A, Chu F, Glenn
D, Chai A and Morris DL: Systematic review of neoadjuvant
transarterial chemoembolization for resectable hepatocellular
carcinoma. Liver Int. 30:166–174. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Kanematsu T, Inokuchi K, Sugimachi K,
Furuta T, Sonoda T, Tamura S and Hasuo K: Selective effects of
lipiodolized antitumor agents. J Surg Oncol. 25:218–226. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Bruix J and Sherman M: Practice Guidelines
Committee, American Association for the Study of Liver Diseases:
Management of hepatocellular carcinoma. Hepatology. 42:1208–1236.
2005. View Article : Google Scholar
|
|
16.
|
Yamasaki T, Kurokawa F, Shirahashi H,
Kusano N, Hironaka K and Okita K: Percutaneous radiofrequency
ablation therapy with combined angiography and computed tomography
assistance for patients with hepatocellular carcinoma. Cancer.
91:1342–1348. 2001. View Article : Google Scholar
|
|
17.
|
[No authors listed]. Intra-arterial
administration of epirubicin in the treatment of nonresectable
hepatocellular carcinoma. Epirubicin Study Group for Hepatocellular
Carcinoma. Cancer Chemother Pharmacol. 19:183–189. 1987.
|
|
18.
|
Kumari R, Sharma A, Ajay AK and Bhat MK:
Mitomycin C induces bystander killing in homogenous and
heterogeneous hepatoma. Molecular Cancer. 8:872009. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Goldberg SN, Grassi CJ, Cardella JF,
Charboneau JW, Dodd GD 3rd, Dupuy DE, Gervais D, Gillams AR, Kane
RA, Lee FT Jr, et al: Society of Interventional Radiology
Technology Assessment Committee; International Working Group on
Image-Guided Tumor Ablation. Image-guided tumor ablation:
Standardization of terminology and reporting criteria. Radiology.
235:728–739. 2005. View Article : Google Scholar
|
|
20.
|
National Cancer Institute (USA): Common
terminology criteria for adverse events, version 3.0. http://ctep.cancer.gov/reporting/ctc.html.
Published August 9, 2006.
|
|
21.
|
Lau WY, Yu SC, Lai EC and Leung TW:
Transarterial chemoembolization for hepatocellular carcinoma. J Am
Coll Surg. 202:155–168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Lau WY, Lai EC, Leung TW and Yu SC:
Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable
hepatocellular carcinoma: a prospective randomized trial-update on
5-year and 10-year survival. Ann Surg. 247:43–48. 2008.PubMed/NCBI
|
|
23.
|
Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ and
P’eng FK: Preoperative transcatheter arterial chemoembolization for
resectable large hepatocellular carcinoma: a reappraisal. Br J
Surg. 82:122–126. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Zhang Z, Liu Q, He J, Yang J, Yang G and
Wu M: The effect of preoperative transcatheter hepatic arterial
chemoembolization on disease-free survival after hepatectomy for
hepatocellular carcinoma. Cancer. 89:2606–2612. 2000. View Article : Google Scholar
|
|
25.
|
Uyama N, Hatano E, Maetani Y, Isoda H,
Shibata T, Taura K, Oe S, Naito M, Yasuchika K, Fujii H, Ikai I and
Uemoto S: Efficacy and toxicity of transcatheter arterial
chemoembolization with cisplatin suspended in lipiodol for
unresectable hepatocellular carcinoma. Gan To Kagaku Ryoho.
35:775–780. 2008.(In Japanese).
|
|
26.
|
Asahina Y, Tsuchiya K, Tamaki N, Hirayama
I, Tanaka T, Sato M, Yasui Y, Hosokawa T, Ueda K, Kuzuya T,
Nakanishi H, et al: Effect of aging on risk for hepatocellular
carcinoma in chronic hepatitis C virus infection. Hepatology.
52:518–527. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Kubo S, Tanaka H, Shuto T, Takemura S,
Yamamoto T, Uenishi T, Tanaka S, Ogawa M, Sakabe K, Yamazaki K and
Hirohashi K: Correlation between low platelet count and
multicentricity of hepatocellular carcinoma in patients with
chronic hepatitis C. Hepatol Res. 30:221–225. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Kobayashi M, Ikeda K, Kawamura Y, Yatsuji
H, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase
Y and Kumada H: High serum des-gamma-carboxy prothrombin level
predicts poor prognosis after radiofrequency ablation of
hepatocellular carcinoma. Cancer. 115:571–580. 2009. View Article : Google Scholar
|
|
29.
|
Mazzaferro V, Romito R, Schiavo M, Mariani
L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli
G, et al: HCC Italian Task Force: Prevention of hepatocellular
carcinoma recurrence with alpha-interferon after liver resection in
HCV cirrhosis. Hepatology. 44:1543–1554. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Kim YS, Lee WJ, Rhim H, Lim HK, Choi D and
Lee JY: The minimal ablative margin of radiofrequency ablation of
hepatocellular carcinoma (>2 and <5 cm) needed to prevent
local tumor progression: 3D quantitative assessment using CT image
fusion. AJR Am J Roentgenol. 195:758–765. 2010.
|
|
31.
|
Ng IO: Prognostic significance of
pathological and biological factors in hepatocellular carcinoma. J
Gastroenterol Hepatol. 13:666–670. 1998. View Article : Google Scholar : PubMed/NCBI
|
